Skip to main content
. 2018 Aug 7;143(9):2200–2212. doi: 10.1002/ijc.31599

Figure 1.

Figure 1

irMSCs increase the survival of GBM‐bearing mice. (a) Outline of the survival study. (b) Survival curves of mice subjected to tumor grafting (GL261), followed by intra‐tumoral niMSCs or 2/5/10/15/20 Gy irMSCs implantation. Animals injected with only GL261 cells were used as control and referred to as tumor‐bearing control (tbc). The animals were followed up to 100 days and data are from 1 to 3 independent experiments with the tbc and niMSC groups included in each experiment (tbc/niMSCs/2/5/10/15/20 Gy irMSCs, n = 22/15/21/14/6/6/6, respectively). Primary MSCs were harvested from bone marrow in 1–2 independent experiments. (c) Analysis of tumor volume and (d) representative H&E stainings; scale bar 500 µm. Data are from one experiment (n = 3–5) and are presented as mean ± SEM. Survival over time is estimated by Kaplan‐Meier analysis and curves are compared by log rank test. Comparisons between groups are performed by one‐way ANOVA, followed by Tukey's multiple comparisons test; *p < 0.05, **p < 0.01, ***p < 0.001.